NCT06441994View on ClinicalTrials.gov

Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 24, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Prostate Cancer
Interventions
DRUG

PSW-1025

PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)

Trial Locations (1)

565-0871

RECRUITING

Osaka University Hospital, Suita

Sponsors
All Listed Sponsors
collaborator

Japan Agency for Medical Research and Development

OTHER_GOV

lead

Osaka University

OTHER